NAD+ shots do not improve ischemia preservation quality

NAD+ shots do not improve ischemia preservation quality.

That is the plain answer. The reason is simple: ischemia preservation is about limiting damage during low oxygen and low blood flow, and the claim that a wellness shot changes that in any useful way is not supported. The evidence that exists is mostly from lab work, animal work, or special organ setups, not from real cryonics cases or from proof that a shot improves preservation quality after ischemia has already started.

I keep the parts of this question separate in my mind. NAD+ is a cell molecule tied to energy use. Ischemia is the time when blood flow drops and cells run short on oxygen and fuel. Preservation quality is not a slogan. It is the real state of the tissue after cooling, transport, and storage, including how much structure and function remain.

That matters because damage from ischemia begins fast. Cells lose energy. Waste builds up. Membranes weaken. Cooling can slow this down, but cooling is the main tool, not a late shot. A treatment that raises NAD+ before an ischemic event in a lab is not the same thing as a wellness shot given around the time tissue is already under stress.

The published science does show one narrow thing. In several ischemia studies, researchers found that maintaining or restoring NAD+ inside cells can help limit injury. Some studies used nicotinamide, NMN, or direct NAD+ in animals or isolated organs. Those results are real, but they do not prove that a marketed NAD+ injection improves preservation quality in the cryonics sense.

That difference is easy to miss. A lab result can show less injury in a heart slice, a mouse brain, or a perfused lung. That is useful science. But preservation quality is a system problem. It depends on timing, temperature, oxygen debt, transport delay, and what happens before and after cooling. A shot cannot undo warm ischemia that has already happened.

I also do not see a clean bridge from “anti-aging shot” to “better preservation.” The wellness pitch is usually broad. It leans on energy, repair, and aging. But ischemia is not general aging. It is an acute failure state. The biology overlaps in places, yet the claim is much larger than the evidence.

There is another limit here that deserves plain words. Most of the supportive work is not in people using consumer NAD+ shots for preservation. It is in controlled experiments with defined doses, defined timing, and defined tissue conditions. That is not the same as real-world use, where delay, dose, route, and tissue state vary a lot.

For cryonics readers, the practical lesson is narrow. Preservation quality is won or lost on fast response, cold care, and good handling of ischemia. A shot marketed for longevity does not change that basic fact. It may alter some cell chemistry in a narrow setting, but that is not the same as making damaged tissue better preserved.

I am careful with the word “may.” Some NAD+ related treatments are still being studied for ischemia-reperfusion injury, where damage comes both from low flow and from return of flow. That is an active research area. But active research is not proof of useful preservation in the field, and it is not proof that NAD+ shots improve the quality of tissue after ischemia.

So the answer stays the same. NAD+ shots do not improve ischemia preservation quality in any proven, practical way. The real work remains the familiar one: reduce delay, reduce warmth, and reduce ischemic damage before it spreads.

Then / Now / Forever keeps that frame in view. Old cryonics claims need to be checked against what actually happened, and the newer paths now being explored need the same hard test.